Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2477499 | 0.86 | HRH4 (0.45) | HRH4HRH3POLB | |
| SCHEMBL14176497 | 0.86 | HRH4 (0.45) | HRH4HRH3POLB | |
| SCHEMBL14176530 | 0.86 | HRH4 (0.45) | HRH4HRH3POLB | |
| SCHEMBL13884287 | 0.86 | HRH4 (0.45) | HRH4HRH3POLB | |
| SCHEMBL13884273 | 0.86 | HRH4 (0.45) | HRH4HRH3POLB | |
| SCHEMBL1276622 | 0.86 | HRH4 (0.45) | HRH4HRH3POLB | |
| SCHEMBL13884243 | 0.86 | HRH4 (0.45) | HRH4HRH3POLB | |
| SCHEMBL13884271 | 0.86 | HRH4 (0.45) | HRH4HRH3POLB | |
| SCHEMBL7834390 | 0.83 | HRH4 (0.43) | HRH4HRH3POLB | |
| SCHEMBL18351665 | 0.80 | HRH4 (0.42) | HRH4HRH3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10646575-B2 | Heterocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20190076541-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Theraprutics, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10646575-B2 | Heterocyclic degronimers for target protein degradation | CRBN, MDM2, STUB1 | HRH4 3248/4885HRH3 2949/4885POLB 4324/4885 |
| US-20190076541-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | CRBN, MDM2, STUB1 | HRH4 3248/4885HRH3 2949/4885POLB 4324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.